Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
174.83
+0.71 (0.41%)
At close: Jan 28, 2026, 4:00 PM EST
173.00
-1.83 (-1.05%)
After-hours: Jan 28, 2026, 7:23 PM EST
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
$1,323,590
Profits / Employee
$211,506
Market Cap
25.65B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | 7,400 | -400 | -5.13% |
| Dec 31, 2018 | 7,800 | 500 | 6.85% |
| Dec 31, 2017 | 7,300 | -100 | -1.35% |
| Dec 31, 2016 | 7,400 | 50 | 0.68% |
| Dec 31, 2015 | 7,350 | -200 | -2.65% |
| Dec 31, 2014 | 7,550 | 700 | 10.22% |
| Dec 31, 2013 | 6,850 | 900 | 15.13% |
| Dec 31, 2012 | 5,950 | 950 | 19.00% |
| Dec 31, 2011 | 5,000 | 150 | 3.09% |
| Dec 31, 2010 | 4,850 | 100 | 2.11% |
| Dec 31, 2009 | 4,750 | 50 | 1.06% |
| Dec 31, 2008 | 4,700 | 400 | 9.30% |
| Dec 31, 2007 | 4,300 | 550 | 14.67% |
| Dec 31, 2006 | 3,750 | 410 | 12.28% |
| Dec 31, 2005 | 3,340 | -926 | -21.71% |
| Dec 31, 2004 | 4,266 | 539 | 14.46% |
| Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
| Jan 31, 2003 | 995 | 303 | 43.79% |
| Jan 31, 2002 | 692 | 199 | 40.37% |
| Jan 31, 2001 | 493 | 86 | 21.13% |
| Jan 31, 2000 | 407 | 42 | 11.51% |
| Jan 31, 1999 | 365 | 26 | 7.67% |
| Dec 31, 1997 | 339 | 71 | 26.49% |
| Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| GSK plc | 68,629 |
| Bristol-Myers Squibb Company | 34,100 |
| Amgen | 28,000 |
BIIB News
- 15 hours ago - Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options - GlobeNewsWire
- 3 days ago - FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - GlobeNewsWire
- 16 days ago - Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - GlobeNewsWire
- 17 days ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 23 days ago - Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China - GlobeNewsWire
- 4 weeks ago - Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge - Seeking Alpha
- 5 weeks ago - The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - GlobeNewsWire